Statement of Changes in Beneficial Ownership (4)
March 03 2020 - 3:39PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Domzalski David |
2. Issuer Name and Ticker or Trading Symbol
Foamix Pharmaceuticals Ltd.
[
FOMX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CEO |
|
(Last)
(First)
(Middle)
C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/2/2020 |
|
(Street)
REHOVOT, L3 7670402
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Ordinary Shares | 3/2/2020 | | A(1) |
V
| 4705 | A | $2.6775 | 324028 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Explanation of Responses: |
| (1) | These shares were acquired under the Foamix Pharmaceuticals Ltd. Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2019 and ending on March 2, 2020 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on December 2, 2019 (the first trading day of the offering period). |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Domzalski David
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLTZMAN STREET
REHOVOT, L3 7670402 | X |
| CEO |
|
Signatures
|
| /s/ Mutya Harsch as attorney-in-fact | | 3/3/2020 |
| **Signature of Reporting Person | Date |
Foamix Pharmaceuticals (NASDAQ:FOMX)
Historical Stock Chart
From Jan 2025 to Feb 2025
Foamix Pharmaceuticals (NASDAQ:FOMX)
Historical Stock Chart
From Feb 2024 to Feb 2025
Real-Time news about Foamix Pharmaceuticals Ltd (NASDAQ): 0 recent articles
More Foamix Pharmaceuticals Ltd. News Articles
